Biomarkers of Efficacy & Durability of Therapeutic Immunomodulation in Autoimmune Diseases: From Preclinical Models to the Clinic

Time: 4:45 pm
day: Conference Day One


  • Use of mouse models of celiac disease and narcolepsy type I for testing efficacy of immunomodulatory compounds
  • Biomarkers of immunomodulation in preclinical models of autoimmune diseases, and their development as exploratory endpoints for clinical trials
  • Assessing durability in preclinical models, to explore persistence or repetitive loss of immune tolerance (once re-established by treatment)